Comparative in vitro activity of Meropenem, Imipenem and Piperacillin/tazobactam against 1071 clinical isolates using 2 different methods: A French multicentre study

BMC Infectious Diseases

Volumn 10, Issue , 2010, Pages

  Joly Guillou, Marie Laure ^a   Kempf, Marie ^a   Cavallo, Jean Didier ^b   Chomarat, Monique ^c   Dubreuil, Luc ^d   Maugein, Jeanne ^e   Muller Serieys, Claudette ^f   Roussel Delvallez, Micheline ^g  

^a ANGERS UNIVERSITY HOSPITAL   (France)

^b SERVICE D ENDOCRINOLOGIE   (France)

^c CENTRE HOSPITALIER LYON SUD   (France)

^d UNIV LILLE   (France)

^e HAUT LÉVÊQUE HOSPITAL   (France)

^f BICHAT HOSPITAL   (France)

^g LILLE UNIVERSITY HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

IMIPENEM; MEROPENEM; PIPERACILLIN PLUS TAZOBACTAM; ANTIINFECTIVE AGENT; DRUG DERIVATIVE; PENICILLANIC ACID; PIPERACILLIN; THIENAMYCIN DERIVATIVE;

AGAR DILUTION; ANTIBACTERIAL ACTIVITY; ARTICLE; BACTERIAL STRAIN; BACTERIUM ISOLATE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DISK DIFFUSION; DRUG SENSITIVITY; ENTEROBACTERIACEAE; EPSILOMETER TEST; ESCHERICHIA COLI; IN VITRO STUDY; INTERMETHOD COMPARISON; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; STAPHYLOCOCCUS; STREPTOCOCCUS; BACTEREMIA; BACTERIAL PNEUMONIA; CLINICAL TRIAL; COMPARATIVE STUDY; DRUG EFFECT; FRANCE; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; HUMAN; ISOLATION AND PURIFICATION; METHODOLOGY; MICROBIOLOGICAL EXAMINATION; MICROBIOLOGY; MULTICENTER STUDY; PERITONITIS; WOUND INFECTION;

ANTI-BACTERIAL AGENTS; BACTEREMIA; FRANCE; GRAM-NEGATIVE BACTERIA; GRAM-POSITIVE BACTERIA; HUMANS; IMIPENEM; MICROBIAL SENSITIVITY TESTS; PENICILLANIC ACID; PERITONITIS; PIPERACILLIN; PNEUMONIA, BACTERIAL; THIENAMYCINS; WOUND INFECTION;

EID: 77952304895     PISSN: None     EISSN: 14712334     Source Type: Journal    
DOI: 10.1186/1471-2334-10-72     Document Type: Article

References (26)

1. Zhanel GG, Wiebe R, Dilay L, Thomson K, Rubinstein E, Hoban DJ, Noreddin AM, Karlowsky JA. Comparative review of the carbapenems. Drugs 2007, 67:1027-1052. 10.2165/00003495-200767070-00006, 17488146.
2. Jones RN, Mendes C, Turner PJ, Masterton R. An overview of the meropenem yearly susceptibility test information collection (MYSTIC) Program: 1997-2004. Diagn Microbiol Infect Dis 2005, 53:247-256. 10.1016/j.diagmicrobio.2005.10.006, 16360548.
3. Unal S, Garcia-Rodriguez JA. Activity of meropenem and comparators against Pseudomonas aeruginosa and Acinetobacter spp. Isolated in the MYSTIC Program, 2002-2004. Diagn Microbiol Infect Dis 2005, 53:265-271. 10.1016/j.diagmicrobio.2005.10.002, 16360550.
4. Masterton RG, Turner PJ. Trends in antimicrobial susceptibility in UK centres: the MYSTIC programme (1997-2002). Int J Antimicrob Agents 2006, 27:69-72. 10.1016/j.ijantimicag.2005.09.011, 16343857.
5. Turner PJ. Meropenem and imipenem activity against Pseudomonas aeruginosa isolates from the MYSTIC Program. Diagn Microbiol Infect Dis 2006, 56:341-344. 10.1016/j.diagmicrobio.2006.07.015, 17049798.
6. Rhomberg PR, Deshpande LM, Kirby JT, Jones RN. Activity of meropenem as serine carbapenemases evolve in US Medical Centers: monitoring report from the MYSTIC Program. Diagn Microbiol Infect Dis 2006, 59:425-432.
7. Rhomberg PR, Jones RN. Contemporary activity of meropenem and comparator broad-spectrum agents: MYSTIC program report from the Unites States component (2005). Diagn Microbiol Infect Dis 2007, 57:207-215. 10.1016/j.diagmicrobio.2006.07.009, 16949243.
8. Jones RN, Kirby JT, Rhomberg PR. Comparative activity of meropenem in US Medical Centers (2007): initiating the 2nd decade MYSTIC Program surveillance. Diagn Microbiol Infect Dis 2008, 61:203-213. 10.1016/j.diagmicrobio.2008.01.017, 18329835.
9. Zhanel GG, DeCorby M, Nichol KA, Wierzbowski A, Baudry PJ, Karlowsky JA, Lagacé-Wiens P, Walkty A, Mulvey MR, Hoban DJ. Antimicrobial susceptibility of 3931 organisms isolated from intensive care units in Canada: Canadian National Intensive Care Unit Study, 2005/2006. Diagn Microbiol Infect Dis 2008, 62:67-80. 10.1016/j.diagmicrobio.2008.04.012, 18513913.
10. Joly-Guillou ML, Cavallo JD, Chomarat M, Dubreuil L, Maugein J, Muller-Serieys C, Roussel-Delvallez M. Comparative activity of meropenem, imipenem and piperacillin/tazobactam against 1118 bacteria involved in hospital infections: a French multicentre study [Abstract]. 18th European Congress of Clinical Microbiology and Infectious Diseases Barcelona 2008, P612.
11. Members of the SFM Antibiogram Committee Comité de l'Antibiogramme de la Société Française de Microbiologie, Report 2003. Int J Antimicrob Agents 2006, 21:364-391. Members of the SFM Antibiogram Committee.
12. Kahlmeter G, Brown DF, Goldstein FW, MacGowan AP, Moutons JW, Odenholt I, Rodloff A, Soussy CJ, Steinbakk M, Soriano F, Stetsiouk O. European Committee on Antimicrobial Susceptibility Testing (EUCAST) Technical Notes on antimicrobial susceptibility testing. Clin Microbiol Infect 2006, 12:501-503. 10.1111/j.1469-0691.2006.01454.x, 16700696.
13. Comité technique national des infections nosocomiales 100 recommandations pour la surveillance et la prévention des infections nosocomiales. 1999, Ministère de l'Emploi et de la Solidarité Secrétariat d'Etat à la Santé et à l'action sociale, Comité technique national des infections nosocomiales.
14. Jones RN, Erwin ME, Hager HL, Hohl PE. Interlaboratory variations of fluoroquinolone susceptibility testing. An international study to validate the quality of microbiology results reported during the fleroxacin clinical trials. Diagn Microbiol Infect Dis 1993, 17:225-232. 10.1016/0732-8893(93)90101-C, 8112032.
15. Jones RN, Gordon KA, Biedenbach DJ. Comparisons of the in vitro susceptibility testing results for garenoxacin using six different national methods: report from the garenoxacin international bridging study. J Antimicrob Chemother 2004, 53:258-265. 10.1093/jac/dkh060, 14729758.
16. Turner PJ. Meropenem activity against European isolates: report on the MYSTIC (Meropenem Yearly Susceptibility Test Information Collection) 2006 results. Diagn Microbiol Infect Dis 2008, 60:185-192. 10.1016/j.diagmicrobio.2007.09.006, 17945455.
17. Goossens H, Grabein B. Prevalence and antimicrobial susceptibility data for extended-spectrum β-lactamase- and Amp C-producing enterobacteriaceae from the MYSTIC Program in Europe and the United States (1997-2004). Diagn Microbiol Infect Dis 2005, 53:257-264. 10.1016/j.diagmicrobio.2005.10.001, 16360549.
18. Hawkey PM. The growing burden of antimicrobial resistance. J Antimicrob Chemother 2008, 62:1-9. 10.1093/jac/dkn241, 2574594, 18441341.
19. Patzer JA, Dzierzanowska D, Turner PJ. Trends in antimicrobial susceptibility of Gram negative isolates from a paediatric intensive care unit in Warsaw: results from the MYSTIC programme (1997-2007). J Antimicrob Chemother 2008, 62:369-375. 10.1093/jac/dkn184, 18445575.
20. Rossolini GM, D'Andrea MM, Mugnaioli C. The spread of CTX-M-type extended-spectrum beta-lactamases. Clin Microbiol Infect 2008, 14(Suppl 1):33-41. 10.1111/j.1469-0691.2007.01867.x, 18154526.
21. Hernández JR, Velasco C, Romero L, Martiìnez-Martiìnez L, Pascual A. Comparative in vitro activity of ertapenem against extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae isolated in Spain. Int J Antimicrob Agents 2006, 28:457-459. 10.1016/j.ijantimicag.2006.08.014, 17008066.
22. Baldwin CM, Lyseng-Williamson KA, Keam SJ. Meropenem: a review of its use in the treatment of serious bacterial infections. Drugs 2008, 68:803-838. 10.2165/00003495-200868060-00006, 18416587.
23. Kahlmete G. An international survey of the antimicrobial susceptibility of pathogens from uncomplicated urinary tract infections: the ECO-SENS Project. J Antimicrob Chemother 2003, 51:69-76. 10.1093/jac/dkg028, 12493789.
24. Nicodemo AC, Araujo MR, Ruiz AS, Gales AC. In vitro susceptibility of Stenotrophomonas maltophilia isolates: comparison of disc diffusion, Etest and agar dilution methods. J Antimicrob Chemother 2004, 53:604-608. 10.1093/jac/dkh128, 14973153.
25. Muramatsu H, Ishikawa J, Nagura O, Horii T. Comparison of susceptibilities for fosfomycin determined by various methods in clinical isolates in 2003-2004. Jpn J Antibiot 2007, 60:107-124.
26. Vázquez JA, Arreaza L, Block C, Ehrhard I, Gray SJ, Heuberger S, Hoffmann S, Kriz P, Nicolas P, Olcen P, Skoczynska A, Spanjaard L, Stefanelli P, Taha MK, Tzanakaki G. Interlaboratory comparison of agar dilution and Etest methods for determining the MICs of antibiotics used in management of Neisseria meningitidis infections. Antimicrob Agents Chemother 2003, 47:3430-3434. 10.1128/AAC.47.11.3430-3434.2003, 253763, 14576098.